Datum Källa Rubrik Typ Alternativ
2021-06-17 Xintela Kallelse till extra bolagsstämma i Xintela AB Pressreleaser Visa Stäng
2021-06-17 Xintela Xintela has completed a directed new share issue raising proceeds of approximately SEK 28 million Pressreleaser Visa Stäng
2021-06-16 Xintela Xintela intends to carry out a directed share issue through an accelerated book building procedure Pressreleaser Visa Stäng
Pressreleaser | 16 Jun 2021 | Xintela

Xintela intends to carry out a directed share issue through an accelerated book building procedure

XINTELA INTENDS TO CARRY OUT A DIRECTED SHARE ISSUE THROUGH AN ACCELERATED BOOK BUILDING PROCEDURE

Lund, 2021-06-16

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, FULLY OR PARTLY, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, HONG KONG, CANADA, JAPAN, NEW ZEALAND, SWITZERLAND, SOUTH AFRICA, SOUTH KOREA, OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE IN ACCORDANCE WITH APPLICABLE LAW.

INSIDE INFORMATION: Xintela AB (publ) (”Xintela” or the ”Company”) hereby announces the Company’s intention to carry out a new share issue, with deviation from the shareholders’ preferential rights of approximately SEK 25 million, with an option to upsize the new share issue, through an accelerated bookbuilding procedure (the ”Directed Issue”). The purpose of the Directed Issue is to finance the start of a clinical phase I/IIa study for stem cell treatment of knee osteoarthritis and within Oncology continue preclinical studies of the Company’s targeted antibodies for the treatment of glioblastoma and triple negative breast cancer. The Directed Issue is intended to be carried out based on the authorization from the Annual General Meeting on 7 May 2021. The Directed Issue will be offered to professional investors. The Company has mandated Vator Securities to investigate the conditions for carrying out the Directed Issue.

Xintela today announces the Company’s intention to carry out a directed new issue, deviating from existing shareholders’ preferential rights, to professional investors of approximately SEK 25 million, with an option to upsize the new share issue, based on the authorization from the Annual General Meeting on 7 May 2021. Xintela has commissioned Vator Securities to investigate the conditions for carrying out the Directed Issue through an accelerated bookbuilding procedure in which the subscription price will also be determined.

The accelerated bookbuilding procedure will begin immediately after the publication of this press release and end before trading on the Nasdaq First North Growth Market commences on 17 June 2021. The Directed Issue is subject to the Board of Director’s decision, which together with pricing and allotment is expected to take place before the commencement of trading on the Nasdaq First North Growth Market on 17 June 2021. The Board of Directors may at any time decide to suspend, shorten or extend the bookbuilding procedure and to refrain in whole or in part from conducting the Directed Issue. The Company will announce the outcome of the Directed Issue when the bookbuilding procedure is completed.

The Company intends to use the net proceeds from the Directed Issue for the following activities: (i) approximately 55 percent to finance the stem cell therapy business area, including the start of a clinical phase I/IIa study on knee osteoarthritis patients (ii) approximately 35 percent to finance the cancer therapy business area , including the continuation of preclinical studies with Xintela’s targeted antibodies in models for glioblastoma and triple negative breast cancer (iii) approximately ten percent to finance the Company’s operations and strengthen Xintela’s working capital.

The reasons for the deviation from the shareholders’ preferential rights are to raise capital in a time- and cost-effective manner on favorable terms and to diversify the shareholder base with qualified and institutional investors.

In connection with the Directed Issue, Board members and members of the Company’s management who own shares have undertaken not to sell any shares in the Company for a period of 180 calendar days from the date of admission to trading of the new shares, with customary terms and exemptions from Vator Securities.

Advisors
Vator Securities is the Sole Bookrunner and Baker McKenzie Advokatbyrå KB is legal advisor to Xintela in connection with the Directed Issue.

This information is such information that Xintela AB (publ) is obliged to make public under the EU Market Abuse Regulation 596/2014. The information was provided by the contact person below for publication at the point in time specified by Xintela’s news distributer beQuoted at the publication of this press release.

The below person may be contacted for further information.

Responsible person:
Evy Lundgren-Åkerlund, CEO
Tel: +46 46 275 65 00
E-mail: evy@xintela.se

For more information, please visit: www.xintela.se

About Xintela

Xintela develops innovative and patent protected cell therapies and targeted cancer therapies based on the marker technology platform XINMARK. The platform is built on specific cell surface proteins (integrins) and more than 25 years of research and development. Xintela uses the marker technology to select and quality assure stem cells (XSTEM) to develop stem cell therapies for diseases that today lack efficient treatment options, including the joint disease osteoarthritis (OA). Xintela has built an in-house GMP-facility for manufacturing of stem cell products and is preparing a First in Human clinical study on patients with knee OA. In the oncology program, Xintela develops antibody-based therapies for treatment of aggressive tumors including glioblastoma and triple-negative breast cancer. Xintela is listed on Nasdaq First North Growth Market Stockholm since 22 March 2016. Xintela’s Certified Adviser at Nasdaq First North Growth Market is Erik Penser Bank AB, +46 8-463 80 00, certifiedadviser@penser.se .

Important information

The release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions and the recipients of this press release in jurisdictions where this press release has been published or distributed shall inform themselves of and follow such legal restrictions. The recipient of this press release is responsible for using this press release, and the information contained herein, in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in Xintela in any jurisdiction, neither from Xintela nor from someone else.

This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended (the ”Securities Act”), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of the securities in the United States. The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, within or into the United States, Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South Africa, Switzerland or in any other jurisdiction where such announcement, publication or distribution of the information would not comply with applicable laws and regulations or where such actions are subject to legal restrictions or would require additional registration or other measures than what is required under Swedish law. Actions taken in violation of this instruction may constitute a crime against applicable securities laws and regulations.

This press release is not a prospectus for the purposes of Regulation (EU) 2017/1129 (the ”Prospectus Regulation”) and has not been approved by any regulatory authority in any jurisdiction. Xintela has not approved any offer to the public of shares or other securities in any of the EEA countries and no prospectus has been or will be prepared in connection with the Directed Issue. In all EEA Member States, this notice is addressed and is addressed only to qualified investors in that Member State within the meaning of the Prospectus Regulation.

In the United Kingdom, this press release and any other materials in relation to the securities described herein is only being distributed to, and is only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, ”qualified investors” (within the meaning of the United Kingdom version of the EU Prospectus Regulation (2017/1129/ EU) which is part of United Kingdom law by virtue of the European Union (Withdrawal) Act 2018) who are (i) persons having professional experience in matters relating to investments who fall within the definition of ”investment professionals” in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the ”Order”); or (ii) high net worth entities falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as ”relevant persons”). In the United Kingdom, any investment or investment activity to which this communication relates is available only to, and will be engaged in only with, relevant persons. Persons who are not relevant persons should not take any action on the basis of this press release and should not act or rely on it.

This press release does not identify or suggest, or purport to identify or suggest, the risks (direct or indirect) that may be associated with an investment in the Company’s shares. Any investment decision to acquire or subscribe for shares in connection with the Directed Issue must be made on the basis of all publicly available information relating to the Company and the Company’s shares. Such information has not been independently verified by the Sole Bookrunner. The Sole Bookrunner is acting for the Company in connection with the Directed Issue and no one else and will not be responsible to anyone other than the Company for providing the protections afforded to its clients nor for giving advice in relation to the Directed Issue or any other matter referred to herein.

This press release does not constitute a recommendation for any investors’ decisions regarding the Directed Issue. Each investor or potential investor should conduct a self-examination, analysis and evaluation of the business and information described in this press release and any publicly available information. The price and value of the securities can decrease as well as increase. Achieved results do not provide guidance for future results. Neither the contents of the Company’s website nor any other website accessible through hyperlinks on the Company’s website are incorporated into or form part of this press release.

Forward-looking statements

This press release contains forward-looking statements that reflect the Company’s intentions, beliefs, or current expectations about and targets for the Company’s and the Group’s future results of operations, financial condition, liquidity, performance, prospects, anticipated growth, strategies and opportunities and the markets in which the Company and the Group operates. Forward-looking statements are statements that are not historical facts and may be identified by words such as ”believe”, ”expect”, ”anticipate”, ”intend”, ”may”, ”plan”, ”estimate”, ”will”, ”should”, ”could”, ”aim” or ”might”, or, in each case, their negative, or similar expressions. The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurances that they will materialize or prove to be correct. Because these statements are based on assumptions or estimates and are subject to risks and uncertainties, the actual results or outcome could differ materially from those set out in the forward-looking statements as a result of many factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The Company does not guarantee that the assumptions underlying the forward-looking statements in this press release are free from errors and readers of this press release should not place undue reliance on the forward-looking statements in this press release. The information, opinions and forward-looking statements that are expressly or implicitly contained herein speak only as of its date and are subject to change without notice. Neither the Company nor anyone else undertake to review, update, confirm or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this press release, unless it is not required by law or Nasdaq First North Premier Growth Market rule book for issuers.

Information to distributors

Solely for the purposes of the product governance requirements contained within: (a) EU Directive 2014/65/EU on markets in financial instruments, as amended (”MiFID II”); (b) Articles 9 and 10 of Commission Delegated Directive (EU) 2017/593 supplementing MiFID II; and (c) local implementing measures (together, the ”MiFID II Product Governance Requirements”), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any ”manufacturer” (for the purposes of the MiFID II Product Governance Requirements) may otherwise have with respect thereto, the shares in Xintela have been subject to a product approval process, which has determined that such shares are: (i) compatible with an end target market of retail investors and investors who meet the criteria of professional clients and eligible counterparties, each as defined in MiFID II; and (ii) eligible for distribution through all distribution channels as are permitted by MiFID II (the ”EU Target Market Assessment”). Solely for the purposes of each manufacturer’s product approval process in the United Kingdom, the target market assessment in respect of the shares in the Company has led to the conclusion that: (i) the target market for such shares is only eligible counterparties, as defined in the FCA Handbook Conduct of Business Sourcebook, and professional clients, as defined in Regulation (EU) No 600/2014 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018 (”UK MiFIR”); and (ii) all channels for distribution of such shares to eligible counterparties and professional clients are appropriate (the ”UK Target Market Assessment” and, together with the EU Target Market Assessment, the ”Target Market Assessment”). Notwithstanding the Target Market Assessment, Distributors should note that: the price of the shares in Xintela may decline and investors could lose all or part of their investment; the shares in Xintela offer no guaranteed income and no capital protection; and an investment in the shares in Xintela is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom. The Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the Directed Issue.

For the avoidance of doubt, the Target Market Assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of MiFID II or UK MiFIR; or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to the shares in Xintela.

Each distributor is responsible for undertaking its own target market assessment in respect of the shares in Xintela and determining appropriate distribution channels.

The following documents can be retrieved from beQuoted
2021-06-16-Xintela-intends-to-carry-out-a-directed-share-iss.pdf

2021-06-16 Xintela Xintela avser att genomföra en riktad nyemission av aktier genom ett accelererat bookbuilding-förfarande Pressreleaser Visa Stäng
2021-05-27 Xintela Xintela AB: BioStock: Xintela's CEO on successful studies and approved GMP facility Pressreleaser Visa Stäng
2021-05-27 Xintela Xintela AB: BioStock: Xintelas vd om studieframgångar och godkänd GMP-anläggning Pressreleaser Visa Stäng
2021-05-21 Xintela Xintela offentliggör delårsrapport för första kvartalet 2021 Rapporter Visa Stäng
2021-05-21 Xintela Xintela offentliggör delårsrapport för första kvartalet 2021 Rapporter Visa Stäng
2021-05-21 Xintela Xintelas GMP-anläggning erhåller tillstånd att producera cellterapiprodukter Pressreleaser Visa Stäng
2021-05-21 Xintela Xintela's GMP facility approved for manufacturing of cell therapy products Pressreleaser Visa Stäng
2021-05-21 Xintela Xintela's GMP facility approved for manufacturing of cell therapy products Pressreleaser Visa Stäng
2021-05-21 Xintela Xintelas GMP-anläggning erhåller tillstånd att producera cellterapiprodukter Pressreleaser Visa Stäng
2021-05-20 Xintela Xintela to develop stem cell therapy for difficult-to-heal wounds Pressreleaser Visa Stäng
2021-05-20 Xintela Xintela utvecklar stamcellsbehandling för svårläkta sår Pressreleaser Visa Stäng
2021-05-20 Xintela Xintela to develop stem cell therapy for difficult-to-heal wounds Pressreleaser Visa Stäng
2021-05-20 Xintela Xintela utvecklar stamcellsbehandling för svårläkta sår Pressreleaser Visa Stäng
2021-05-18 Xintela Xintela's stem cell product XSTEM repairs cartilage damage in preclinical model Pressreleaser Visa Stäng
2021-05-18 Xintela Xintelas stamcellsprodukt XSTEM reparerar skadat ledbrosk i preklinisk modell Pressreleaser Visa Stäng
2021-05-18 Xintela Xintelas stamcellsprodukt XSTEM reparerar skadat ledbrosk i preklinisk modell Pressreleaser Visa Stäng
2021-05-18 Xintela Xintela's stem cell product XSTEM repairs cartilage damage in preclinical model Pressreleaser Visa Stäng
2021-05-11 Xintela Xintela AB: BioStock: New CEO for Xintela's subsidiary Targinta Pressreleaser Visa Stäng
2021-05-11 Xintela Xintela AB: BioStock: Ny vd för Xintelas dotterbolag Targinta Pressreleaser Visa Stäng
2021-05-07 Xintela Kommuniké från Xintelas årsstämma 2021 Pressreleaser Visa Stäng
2021-05-07 Xintela Kommuniké från Xintelas årsstämma 2021 Pressreleaser Visa Stäng
2021-05-04 Xintela Targinta rekryterar Per Norlén som VD Pressreleaser Visa Stäng
2021-05-04 Xintela Targinta recruits Per Norlén as CEO Pressreleaser Visa Stäng
2021-05-04 Xintela Targinta rekryterar Per Norlén som VD Pressreleaser Visa Stäng
2021-05-04 Xintela Targinta recruits Per Norlén as CEO Pressreleaser Visa Stäng
2021-04-16 Xintela Xintela offentliggör årsredovisning för 2020 Rapporter Visa Stäng
2021-04-12 Xintela Inspektion av Xintelas GMP-verksamhet för tillverkningstillstånd genomförd Pressreleaser Visa Stäng
2021-04-12 Xintela Xintela GMP inspection for manufacturing license completed Pressreleaser Visa Stäng
2021-04-09 Xintela KALLELSE TILL ÅRSSTÄMMA I XINTELA AB (PUBL) Pressreleaser Visa Stäng
2021-04-06 Xintela Xintela rapporterar positiva resultat från preklinisk ARDS studie och erhåller nytt anslag om 2,3 miljoner kronor Pressreleaser Visa Stäng
2021-04-06 Xintela Xintela reports positive results from preclinical ARDS study and new grant of 2.3 million SEK Pressreleaser Visa Stäng
2021-03-30 Xintela Xintela AB: BioStock: Xintela's CEO on recent successes Pressreleaser Visa Stäng
2021-03-30 Xintela Xintela AB: BioStock: Xintelas vd om senaste tidens framgångar Pressreleaser Visa Stäng
2021-03-19 Xintela Xintela gets tissue establishment license Pressreleaser Visa Stäng
2021-03-19 Xintela Xintela erhåller tillstånd för vävnadsinrättning Pressreleaser Visa Stäng
2021-03-17 Xintela Xintela gets patent grant in Europe for XSTEM stem cell product Pressreleaser Visa Stäng
2021-03-17 Xintela Xintela erhåller godkänt patent i Europa för sin stamcellsprodukt XSTEM Pressreleaser Visa Stäng
2021-03-12 Xintela Xintela publishes results from glioblastoma antibody study Pressreleaser Visa Stäng
2021-03-12 Xintela Xintela publicerar antikroppsresultat från glioblastomstudie Pressreleaser Visa Stäng
2021-02-26 Xintela Year-end report 1 Jan - 31 Dec 2020 Rapporter Visa Stäng
2021-02-26 Xintela Bokslutskommuniké 2020-01-01 till 2020-12-31 Rapporter Visa Stäng
2021-01-29 Xintela Xintela AB: BioStock: Xintela is preparing for progress in 2021 Pressreleaser Visa Stäng
2021-01-29 Xintela Xintela AB: BioStock: Xintela laddar för avancemang under 2021 Pressreleaser Visa Stäng
2021-01-19 Xintela Rättelse: Uppdatering tidigare pressmeddelande "Xintela AB har genomfört en kvittningsemission av aktier om 9,5 MSEK" Pressreleaser Visa Stäng
2021-01-12 Xintela Xintela AB har genomfört en kvittningsemission av aktier om 9,5 MSEK Pressreleaser Visa Stäng
2021-01-07 Xintela Xintela erhåller Notice of Allowance från USPTO för behandling av tumörer i hjärnan Pressreleaser Visa Stäng
2021-01-07 Xintela Xintela receives Notice of Allowance from USPTO for the treatment of brain tumors Pressreleaser Visa Stäng
2020-12-21 Xintela Xintela submits manufacturing license application Pressreleaser Visa Stäng
2020-12-21 Xintela Xintela skickar in ansökan om tillverkningstillstånd Pressreleaser Visa Stäng
2020-12-14 Xintela Xintela recruits Jeffrey Abbey to Targinta Pressreleaser Visa Stäng
2020-12-14 Xintela Xintela rekryterar Jeffrey Abbey till Targinta Pressreleaser Visa Stäng
2020-12-04 Xintela Arbitral award rendered in favour of Xintela in dispute with former underwriters Pressreleaser Visa Stäng
2020-12-04 Xintela Skiljedom meddelad till Xintelas fördel i tvist med tidigare garanter Pressreleaser Visa Stäng
2020-12-03 Xintela Xintela Board recommends Maarten de Château as new Board member Pressreleaser Visa Stäng
2020-12-03 Xintela Xintelas styrelse föreslår Maarten de Château som ny styrelseledamot Pressreleaser Visa Stäng
2020-11-27 Xintela Xintela offentliggör delårsrapport för tredje kvartalet 2020 Rapporter Visa Stäng
2020-11-27 Xintela Xintela publishes interim report for the third quarter of 2020 Rapporter Visa Stäng
2020-11-23 Xintela Xintela AB offentliggör utfallet av nyttjandet av teckningsoptioner av serie TO 2 Pressreleaser Visa Stäng
2020-11-12 Xintela Xintelas styrelse föreslår Lars Hedbys som ny styrelseledamot Pressreleaser Visa Stäng
2020-11-12 Xintela Xintela Board recommends Lars Hedbys as new Board member Pressreleaser Visa Stäng
2020-11-09 Xintela Xintela AB: BioStock: Xintela's CEO comments on the positive patent notice Pressreleaser Visa Stäng
2020-11-09 Xintela Xintela AB: BioStock: Xintelas vd kommenterar det positiva patentbeskedet Pressreleaser Visa Stäng
2020-11-02 Xintela Lösenpris fastställt avseende teckningsoptioner av serie TO 2 i Xintela AB, där teckningsperioden inleds den 4 november 2020 Pressreleaser Visa Stäng
2020-10-30 Xintela Nulägesanalys av Xintela publicerad Pressreleaser Visa Stäng
2020-10-30 Xintela Status report of Xintela published Pressreleaser Visa Stäng
2020-10-30 Xintela Xintela AB: BioStock: Status report Xintela - Integrins marking the future Pressreleaser Visa Stäng
2020-10-30 Xintela Xintela AB: BioStock: Nulägesanalys Xintela - Integrins marking the future Pressreleaser Visa Stäng
2020-10-29 Xintela Xintela erhåller preliminärt godkännande av Europapatentverket för sin stamcellsprodukt XSTEM Pressreleaser Visa Stäng
2020-10-29 Xintela Xintela receives 'intention to grant' decision from European Patent Office for stem cell product XSTEM Pressreleaser Visa Stäng
2020-10-28 Xintela Xintela applies for tissue establishment license Pressreleaser Visa Stäng
2020-10-28 Xintela Xintela ansöker om tillstånd för vävnadsinrättning Pressreleaser Visa Stäng
2020-10-26 Xintela Xintela AB: BioStock: Xintela reports promising results in Covid-19 project Pressreleaser Visa Stäng
2020-10-26 Xintela Xintela AB: BioStock: Xintela rapporterar lovande resultat i Covid-19 projekt Pressreleaser Visa Stäng
2020-10-26 Xintela Xintelas stamceller visar lovande resultat i preklinisk ARDS studie Pressreleaser Visa Stäng
2020-10-26 Xintela Xintela's stem cells show promising results in preclinical ARDS study Pressreleaser Visa Stäng
2020-10-16 Xintela Xintela AB: BioStock Studio: Xintela på kurs mot viktiga milstolpar Pressreleaser Visa Stäng
2020-08-28 Xintela Xintela offentliggör delårsrapport för andra kvartalet 2020 Rapporter Visa Stäng
2020-08-19 Xintela Xintela expands and strengthens management team Pressreleaser Visa Stäng
2020-08-19 Xintela Xintela utökar och förstärker ledningen Pressreleaser Visa Stäng
2020-07-29 Xintela Xintela erhåller Notice of Allowance från USPTO för kvalitetssäkring av broskcellsbaserade produkter Pressreleaser Visa Stäng
2020-07-29 Xintela Xintela receives Notice of Allowance from USPTO for quality assurance of chondrocyte-based products Pressreleaser Visa Stäng
2020-07-13 Xintela Xintelas fullt garanterade företrädesemission av units kraftigt övertecknad - utnyttjar Utökningsoptionen Pressreleaser Visa Stäng
2020-07-02 Xintela Xintela AB: BioStock studio: Xintela finns på större aktörers radar Pressreleaser Visa Stäng
2020-06-30 Xintela Xintela AB: BioStock: Företrädesemission ska ta Xintela till nästa nivå Pressreleaser Visa Stäng
2020-06-29 Xintela Xintela AB: BioStock studio: Xintela om den pågående emissionen Pressreleaser Ladda ner | Visa Stäng
2020-06-23 Xintela Xintela offentliggör prospekt avseende fullt garanterad företrädesemission av units om cirka 37 MSEK Pressreleaser Visa Stäng
2020-06-23 Xintela Xintela erhåller preliminärt godkännande av Europapatentverket för behandling av tumörer i hjärnan Pressreleaser Visa Stäng
2020-06-23 Xintela Xintela granted preliminary approval from the European Patent Office for the treatment of brain tumors Pressreleaser Visa Stäng
2020-06-23 Xintela Xintela erhåller teckningsåtagande om cirka 3 MSEK från Bauerfeind Group i Bolagets fullt garanterade företrädesemission om cirka 37 MSEK Pressreleaser Visa Stäng
2020-06-17 Xintela Xintela develops treatment for aggressive breast cancer Pressreleaser Visa Stäng
2020-06-17 Xintela Xintela utvecklar behandling för aggressiv bröstcancer Pressreleaser Visa Stäng
2020-06-12 Xintela Xintela avser genomföra fullt garanterad företrädesemission av units om cirka 37 MSEK Pressreleaser Visa Stäng
2020-06-09 Xintela Kommuniké från Xintelas årsstämma 2020 Pressreleaser Visa Stäng
2020-05-29 Xintela Xintela offentliggör delårsrapport för första kvartalet 2020 Rapporter Visa Stäng
2020-05-26 Xintela Xintela offentliggör årsredovisning för 2019 Rapporter Visa Stäng
2020-05-22 Xintela Xintela säkrar ytterligare finansiering; upptar lån om 18,9 miljoner kronor med konverteringsmöjlighet Pressreleaser Visa Stäng
2020-05-15 Xintela Xintela AB: BioStock: Stamceller i fokus när Xintela får miljonbidrag för covid-19 projekt Pressreleaser Visa Stäng
2020-05-12 Xintela KALLELSE TILL ÅRSSTÄMMA I XINTELA AB (PUBL) Pressreleaser Visa Stäng
2020-05-08 Xintela Xintela granted 1 million SEK from Vinnova Pressreleaser Visa Stäng
2020-05-08 Xintela Xintela beviljas 1 miljon kronor från Vinnova Pressreleaser Visa Stäng
2020-05-01 Xintela Xintela AB årsstämma - nytt datum för stämman Pressreleaser Visa Stäng
2020-03-30 Xintela Xintela AB: BioStock: Xintelas cancerprojekt tilldelas två miljoner kronor av Vinnova Pressreleaser Visa Stäng
2020-03-27 Xintela Xintela granted 2 million SEK from Vinnova Pressreleaser Visa Stäng
2020-03-27 Xintela Xintela beviljas 2 miljoner kronor från Vinnova Pressreleaser Visa Stäng
2020-02-28 Xintela Bokslutskommuniké 2019-01-01 till 2019-12-31 Rapporter Visa Stäng
2020-02-27 Xintela Xintela AB: BioStock: Xintela blickar framåt Pressreleaser Visa Stäng
2020-02-03 Xintela Xintela AB: BioStock: Flerfrontsavancemang för Xintela Pressreleaser Visa Stäng
2020-02-03 Xintela Xintela publishes positive preclinical results from equine study Pressreleaser Visa Stäng
2020-02-03 Xintela Xintela publicerar positiva prekliniska resultat från häststudie Pressreleaser Visa Stäng
2019-12-27 Xintela Xintela konverterar lån om ca 8 MSEK och tar in nytt lån om 10 MSEK Pressreleaser Visa Stäng
2019-12-16 Xintela Xintela AB: BioStock: Xintelas dotterbolag nådde milstolpe i cancerprojekt Pressreleaser Visa Stäng
2019-12-11 Xintela Positiva prekliniska resultat i Xintelas glioblastomprojekt Pressreleaser Visa Stäng
2019-12-11 Xintela Xintela AB: BioStock: Lån från Bauerfeind AG signalerar stark tilltro till Xintela Pressreleaser Visa Stäng
2019-11-29 Xintela Xintela offentliggör delårsrapport för tredje kvartalet Rapporter Visa Stäng
2019-11-05 Xintela Xintela erhåller lån om ca 8 MSEK Pressreleaser Visa Stäng
2019-08-30 Xintela Xintela offentliggör delårsrapport för andra kvartalet Rapporter Visa Stäng
2019-05-27 Xintela Kommuniké från Xintelas årsstämma 2019 Pressreleaser Visa Stäng
2019-05-23 Xintela Xintela offentliggör delårsrapport för första kvartalet Rapporter Visa Stäng
2019-05-06 Xintela Xintela offentliggör årsredovisning för 2018 Rapporter Visa Stäng
2019-04-26 Xintela Xintela publicerar resultat fran glioblastomstudie Pressreleaser Visa Stäng
2019-04-26 Xintela Kallelse till årsstämma i Xintela AB (publ) Pressreleaser Visa Stäng
2019-04-26 Xintela Peter Edman föreslås som ny styrelseledamot Pressreleaser Visa Stäng
2019-04-16 Xintela Xintela utser Sven Kili som Chief Operating Officer Pressreleaser Visa Stäng
2019-02-27 Xintela Bokslutskommuniké 2018 Rapporter Visa Stäng
2019-02-15 Xintela Xintela publicerar nya resultat från stamcellsstudie Pressreleaser Visa Stäng
2018-11-30 Xintela Konvertering av konvertibler i Xintela Pressreleaser Visa Stäng
2018-11-28 Xintela Delårsrapport 2018-01-01 till 2018-09-30 Rapporter Visa Stäng
2018-10-25 Xintela XINTELA AND CATALENT TO CO-DEVELOP BRAIN CANCER THERAPY Pressreleaser Ladda ner | Visa Stäng
2018-09-28 Xintela KALLELSE TILL EXTRA BOLAGSSTÄMMA I XINTELA AB (publ) Pressreleaser Ladda ner | Visa Stäng
2018-09-28 Xintela XINTELA BESLUTAR OM RIKTAD NYEMISSION TILL BAUERFEIND AG OM CIRKA 50 MSEK Pressreleaser Ladda ner | Visa Stäng
2018-09-24 Xintela Xintela avbryter företrädesemission och avser att genomföra en riktad emission till strategisk investerare om minst 25 MSEK till emissionskursen 6 kr Pressreleaser Ladda ner | Visa Stäng
2018-09-21 Xintela KOMMUNIKÉ FRÅN XINTELA AB:s EXTRA BOLAGSSTÄMMA 2018 Pressreleaser Ladda ner | Visa Stäng
2018-09-05 Xintela KALLELSE TILL EXTRA BOLAGSSTÄMMA I XINTELA AB (publ) Pressreleaser Ladda ner | Visa Stäng
2018-09-05 Xintela XINTELA BESLUTAR OM FÖRETRÄDESEMISSION OM CIRKA 24,8 MSEK VILLKORAT AV GODKÄNNANDE VID EXTRA BOLAGSSTÄMMA Pressreleaser Ladda ner | Visa Stäng
2018-08-29 Xintela DELÅRSRAPPORT 2018-01-01 till 2018-06-30 Rapporter Ladda ner | Visa Stäng
2018-08-29 Xintela SVEN KILI TAKES ROLE AS CHIEF MEDICAL OFFICER IN XINTELA Pressreleaser Ladda ner | Visa Stäng
2018-08-29 Xintela SVEN KILI TAR ROLLEN SOM CHIEF MEDICAL OFFICER I XINTELA Pressreleaser Ladda ner | Visa Stäng
2018-08-29 Xintela XINTELA KNOPPAR AV ONKOLOGIVERKSAMHETEN Pressreleaser Ladda ner | Visa Stäng
2018-08-29 Xintela XINTELA TO SPIN OUT ONCOLOGY BUSINESS Pressreleaser Ladda ner | Visa Stäng
2018-08-21 Xintela Significant progress in Xintela Pressreleaser Ladda ner | Visa Stäng
2018-08-21 Xintela Viktiga framsteg i Xintela Pressreleaser Ladda ner | Visa Stäng
2018-08-09 Xintela Xintela utvidgar patentskyddet inom degenerativa ledsjukdomar Pressreleaser Ladda ner | Visa Stäng
2018-08-09 Xintela Xintela extends patent protection for degenerative joint diseases Pressreleaser Ladda ner | Visa Stäng
2018-07-09 Xintela Xintela tecknar Letter of Intent med CO.DON Pressreleaser Ladda ner | Visa Stäng
2018-07-09 Xintela Xintela signs Letter of Intent with CO.DON Pressreleaser Ladda ner | Visa Stäng
2018-06-28 Xintela Xintela erhåller MUMS-status för behandling av artros hos hästar Pressreleaser Ladda ner | Visa Stäng
2018-06-28 Xintela Xintela receives MUMS-status for the treatment of osteoarthritis in horses Pressreleaser Ladda ner | Visa Stäng
2018-05-31 Xintela Xintela beslutar om konvertibelt lån om 5 MSEK Pressreleaser Ladda ner | Visa Stäng
2018-05-29 Xintela KOMMUNIKÈ FRÅN XINTELAS ÅRSSTÄMMA 2018 Pressreleaser Ladda ner | Visa Stäng
2018-05-25 Xintela Delårsrapport 2018-01-01 till 2018-03-31 Rapporter Ladda ner | Visa Stäng
2018-05-15 Xintela Xintela offentliggör årsredovisning för 2017 Rapporter Ladda ner | Visa Stäng
2018-04-27 Xintela KALLELSE TILL ÅRSSTÄMMA I XINTELA Pressreleaser Ladda ner | Visa Stäng
2018-04-26 Xintela Xintela's GMP facility is completed and being prepared for production and clinical trials Pressreleaser Ladda ner | Visa Stäng
2018-04-26 Xintela Xintelas GMP-anläggning är färdigbyggd och förbereds för produktion och kliniska studier Pressreleaser Ladda ner | Visa Stäng
2018-04-17 Xintela XINTELA DEVELOPS UNIQUE METHODS IN STEM CELL THERAPY FOR THE BRAIN AND BROADENS PATENT PORTFOLIO Pressreleaser Ladda ner | Visa Stäng
2018-04-17 Xintela XINTELA UTVECKLAR UNIKA METODER FÖR STAMCELLSBEHANDLING AV HJÄRNAN OCH BREDDAR PATENTPORTFÖLJEN Pressreleaser Ladda ner | Visa Stäng
2018-03-20 Xintela Xintela förbereder avknoppning av onkologiverksamheten till separat bolag Pressreleaser Ladda ner | Visa Stäng
2018-03-20 Xintela Xintela prepares for oncology spinout Pressreleaser Ladda ner | Visa Stäng
2018-02-22 Xintela Bokslutskommuniké 2017-01-01 till 2017-12-31 Rapporter Ladda ner | Visa Stäng
2017-12-29 Xintela Xintela licenses human antibody technology for cancer therapy Pressreleaser Ladda ner | Visa Stäng
2017-12-29 Xintela Xintela licensierar antikroppsteknologi för utveckling av cancerterapi Pressreleaser Ladda ner | Visa Stäng
2017-12-19 Xintela Xintela inleder samarbete med det japanska bolaget CellSeed Pressreleaser Ladda ner | Visa Stäng
2017-12-19 Xintela Xintela to collaborate with Japanese Cellseed Pressreleaser Ladda ner | Visa Stäng
2017-12-01 Xintela Xintela tillförs cirka 500 KSEK efter inlösen av teckningsoptioner Pressreleaser Ladda ner | Visa Stäng
2017-11-23 Xintela Delårsrapport 2017-01-01 till 2017-09-30 Rapporter Ladda ner | Visa Stäng
2017-11-13 Xintela Xintela raises 17 million SEK in debt and equity Pressreleaser Ladda ner | Visa Stäng
2017-11-13 Xintela Xintela stärker kassan med 17 MSEK genom riktad nyemission och lån Pressreleaser Ladda ner | Visa Stäng
2017-10-17 Xintela Keld Søndergaard leaves Xintela's Board of Directors Pressreleaser Ladda ner | Visa Stäng
2017-10-17 Xintela Keld Søndergaard lämnar Xintelas styrelse Pressreleaser Ladda ner | Visa Stäng
2017-09-11 Xintela Xintela building own GMP-facility for stem cell production Pressreleaser Ladda ner | Visa Stäng
2017-09-11 Xintela Xintela uppför egen GMP-anläggning för produktion av stamceller Pressreleaser Ladda ner | Visa Stäng
2017-08-30 Xintela Halvårsrapport 2017-01-01 till 2017-06-30 Rapporter Ladda ner | Visa Stäng
2017-07-17 Xintela Xintela recruits Liselotte Theorell as Birector Product Development and Quality Management Pressreleaser Ladda ner | Visa Stäng
2017-07-17 Xintela Xintela rekryterar Liselotte Theorell som ansvarig för produktutveckling och kvalitetsledning Pressreleaser Ladda ner | Visa Stäng
2017-06-22 Xintela Xintela participates in multi-million, government funded initiative to form a cell and gene therapy research center Pressreleaser Ladda ner | Visa Stäng
2017-06-22 Xintela Xintela är partner i statlig mångmiljonsatsning på forskningscentrum för cell- och genterapi Pressreleaser Ladda ner | Visa Stäng
2017-05-22 Xintela Xintela tecknar samförståndsavtal med CO.DON Pressreleaser Ladda ner | Visa Stäng
2017-05-22 Xintela Xintela signs memorandum of understanding with CO.DON Pressreleaser Ladda ner | Visa Stäng
2017-05-19 Xintela Kommunikè från Xintelas årsstämma 2017 Pressreleaser Ladda ner | Visa Stäng
2017-05-18 Xintela Delårsrapport 2017-01-01 till 2017-03-31 Rapporter Ladda ner | Visa Stäng
2017-05-09 Xintela Keld Søndergaard nominated as new board member Pressreleaser Ladda ner | Visa Stäng
2017-05-09 Xintela Keld Søndergaard föreslås som ny styrelseledamot Pressreleaser Ladda ner | Visa Stäng
2017-04-27 Xintela Xintela offentliggör årsredovisning för 2016 Rapporter Ladda ner | Visa Stäng
2017-04-18 Xintela Kallelse till årsstämma i Xintela Pressreleaser Ladda ner | Visa Stäng
2017-03-21 Xintela Xintela strengthens business development and reorganizes Pressreleaser Ladda ner | Visa Stäng
2017-03-21 Xintela Xintela förstärker affärsutveckling och omorganiserar Pressreleaser Ladda ner | Visa Stäng
2017-02-28 Xintela Bokslutskommuniké 2016-01-01 till 2016-12-31 Rapporter Ladda ner | Visa Stäng
2017-02-15 Xintela Xintela tillförs cirka 10 MSEK genom nyttjande av teckningsoptioner av serie TO1 Pressreleaser Ladda ner | Visa Stäng
2017-02-08 Xintela Insynspersoner och huvudägare avser nyttja teckningsoptioner av serie TO 1 Pressreleaser Ladda ner | Visa Stäng
2017-01-30 Xintela Idag inleds teckningsperioden för teckningsoptioner av serie TO1 Pressreleaser Ladda ner | Visa Stäng
2017-01-20 Xintela Xintela rapporterar positiva prekliniska resultat i cancerprojekt Pressreleaser Ladda ner | Visa Stäng
2017-01-20 Xintela Xintela reports positive preclinical results in cancer project Pressreleaser Ladda ner | Visa Stäng
2017-01-04 Xintela Xintelas stamceller visar positiva behandlingseffekter på broskskada i häststudie Pressreleaser Ladda ner | Visa Stäng
2017-01-04 Xintela Xintela's stem cells show positive treatment effects on cartilage damage in horse study Pressreleaser Ladda ner | Visa Stäng

Kommande händelser

9 May 2017 | Kvartalsrapport 2017-Q1
18 May 2017 | Årsstämma 2016
19 May 2017 | Årligutdelning 2017
8 Aug 2017 | Kvartalsrapport 2017-Q2
30 Aug 2017 | Kvartalsrapport 2017-Q2
31 Oct 2017 | Kvartalsrapport 2017-Q3
22 Nov 2017 | Kvartalsrapport 2017-Q3
23 Nov 2017 | Kvartalsrapport 2017-Q3
22 Jan 2018 | Bokslutskommuniké 2017
22 Feb 2018 | Bokslutskommuniké 2017
22 Feb 2018 | Bokslutskommuniké 2017
25 May 2018 | Kvartalsrapport 2018-Q1
29 May 2018 | Årsstämma 2017
30 May 2018 | Årligutdelning
29 Aug 2018 | Kvartalsrapport 2018-Q2
21 Sep 2018 | Extrastämma 2018
28 Nov 2018 | Kvartalsrapport 2018-Q3
27 Feb 2019 | Bokslutskommuniké 2018
23 May 2019 | Kvartalsrapport 2019-Q1
27 May 2019 | Årsstämma 2018
28 May 2019 | Årligutdelning
30 Aug 2019 | Kvartalsrapport 2019-Q2
28 Feb 2020 | Bokslutskommuniké 2019
29 May 2020 | Årsstämma 2019
29 May 2020 | Kvartalsrapport 2020-Q1
1 Jun 2020 | Årligutdelning
9 Jun 2020 | Årsstämma 2019
10 Jun 2020 | Årligutdelning
28 Aug 2020 | Kvartalsrapport 2020-Q2
27 Nov 2020 | Kvartalsrapport 2020-Q3
26 Feb 2021 | Bokslutskommuniké 2020
7 May 2021 | Årsstämma 2020
10 May 2021 | Årligutdelning
21 May 2021 | Kvartalsrapport 2021-Q1
5 Jul 2021 | Extrastämma 2021
27 Aug 2021 | Kvartalsrapport 2021-Q2
19 Nov 2021 | Kvartalsrapport 2021-Q3
17 Jan 2022 | Extrastämma 2022
25 Feb 2022 | Bokslutskommuniké 2021
6 May 2022 | Årsstämma 2021
9 May 2022 | Årligutdelning
20 May 2022 | Kvartalsrapport 2022-Q1
26 Aug 2022 | Kvartalsrapport 2022-Q2
25 Nov 2022 | Kvartalsrapport 2022-Q3
24 Feb 2023 | Bokslutskommuniké 2022